生育药物和癌症:一个指南
Fertility and sterility
|May 4, 2024
概括
虽然生育药物与乳腺癌,结肠癌或宫癌无关,但使用它们的女性应该知道卵巢癌和甲状腺癌的潜在风险增加. 对于其他类型的癌症还需要进一步的研究.
科学领域:
- 生殖医学 生殖医学
- 在瘤学瘤学.
- 流行病学 流行病学
背景情况:
- 调查生育治疗与癌症风险之间的联系是复杂的,因为混因素.
- 经历不孕不育的女性可能有先前存在的疾病,增加癌症风险.
研究的目的:
- 评估生育药物使用与患各种癌症的风险之间的关联.
- 为了澄清接受生育治疗的女性潜在的癌症风险.
主要方法:
- 审查现有的流行病学数据和关于生育药物使用和癌症发病率的研究.
- 分析确定因果关系的方法挑战,包括混变量和延迟期.
主要成果:
- 在生育药物和乳腺癌,结肠癌或宫癌之间没有明确的联系.
- 关于黑色素瘤和非霍奇金淋巴瘤风险的数据不够.
- 发现了侵入性/边缘性卵巢癌和甲状腺癌的潜在风险增加,尽管因果关系仍在争论中.
结论:
- 生育药物与最常见的癌症没有明确的联系.
- 妇女应该被告知潜在的特定癌症的高风险,如卵巢和甲状腺癌.
- 区分药物影响与潜在的不孕或其他因素仍然是一个挑战.
相关概念视频
Cancer Prevention
6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.2K
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Spermatogenesis
102.4K
Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male...
102.4K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


